Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Why a COVID-19 trial is exciting BOD (ASX:BOD) investors today?
These 3 ASX Healthcare shares are running hot today
Share Market News
Why the Bod (ASX:BDA) share price is climbing today
Up 21%, why the Bod (ASX:BDA) share price is smoking the market today
Share Market News
Bod (ASX:BDA) share price soars on United States market entry
Share Market News
Why the Bod (ASX:BDA) share price is tracking 5% higher today
Share Market News
Why the Bod (ASX:BDA) share price is soaring 11%
Why Atomos, BOD Australia, Galaxy, & Zebit shares are racing higher
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Bod Australia Ltd is engaged in the development and manufacturing of premium CBD and hemp products for consumer markets in Australia and The United Kingdom. It also engages in the development, manufacture, and distribution of therapeutics medicinal cannabis products based on Good Manufacturing Practice. It is organized into three operating segments: medical, over the counter cannabidiol/Hemp ('OTC CBD/Hemp'), and OTC Herbals out of which the OTC CBD/Hemp segment derives the majority revenue.
|13 May 2022||$0.14||$-0.01||-6.67%||52,443||$0.14||$0.14||$0.13|
|12 May 2022||$0.15||$-0.01||-6.25%||231,545||$0.15||$0.16||$0.14|
|11 May 2022||$0.16||$0.02||13.79%||79,079||$0.15||$0.16||$0.15|
|10 May 2022||$0.15||$-0.01||-6.67%||223,793||$0.15||$0.15||$0.14|
|09 May 2022||$0.15||$-0.02||-12.12%||326,427||$0.15||$0.16||$0.14|
|06 May 2022||$0.17||$0.00||0.00%||81,471||$0.14||$0.17||$0.14|
|05 May 2022||$0.17||$0.00||0.00%||47,008||$0.17||$0.17||$0.16|
|04 May 2022||$0.17||$0.02||13.33%||88,013||$0.16||$0.17||$0.15|
|03 May 2022||$0.15||$-0.02||-12.12%||276,795||$0.16||$0.16||$0.15|
|02 May 2022||$0.17||$-0.01||-5.88%||149,781||$0.17||$0.17||$0.16|
|29 Apr 2022||$0.17||$0.00||0.00%||17,882||$0.17||$0.17||$0.15|
|28 Apr 2022||$0.17||$0.01||6.25%||31,713||$0.16||$0.17||$0.15|
|27 Apr 2022||$0.16||$0.00||0.00%||15,500||$0.16||$0.16||$0.16|
|26 Apr 2022||$0.16||$-0.01||-5.88%||255,391||$0.17||$0.17||$0.15|
|22 Apr 2022||$0.17||$0.00||0.00%||95,892||$0.17||$0.17||$0.16|
|21 Apr 2022||$0.17||$0.01||6.25%||13,231||$0.16||$0.18||$0.16|
|20 Apr 2022||$0.16||$-0.01||-6.06%||42,000||$0.18||$0.18||$0.16|
|Mr David Lewis Baker||Non-Executive Director||Apr 2022||
Mr Baker is a commercial advisor and company director with over 40 years of experience in law, investment banking, public company leadership and corporate governance. He has deep industry knowledge across a range of sectors and understanding of financial markets. Mr Baker is a co-founder of Baker Cook Advisory which is a boutique provider of outsourced legal, commercial and governance advice and mediation services for corporations and government agencies.
|Ms Joanne (Jo) Patterson||Chief Executive OfficerExecutive Director||Oct 2016||
Ms Patterson has over 20 years of experience in business and corporate strategy with exposure in Australia and international markets. She has developed a number of businesses from start-up as well as driving established organisations. Jo has held multiple CEO and Managing Director roles over her career.
|Mr George Livery||Non-Executive Director||Sep 2018||
Mr Livery has over 25 years of experience in senior roles domestically and internationally. Most relevant are his last seven years as director of strategy and corporate development at Swisse Wellness Group, a market leading wellness brand. In addition, George's executive experience is culminated in positions across multiple other industries including the role of chief executive officer at Village Cinemas Australia, chief operating officer of Village International, commercial director at Hoyts Limited, and director of operations and marketing (non-academic services) at the University of Sydney.
|Mr Akash Bedi||Non-Executive Director||Jul 2019||
Mr Bedi is Group Senior Director of Strategy and Corporate Affairs at H&H Group. He is based in Hong Kong and is responsible for leading H&H Group's strategy and business development including mergers and acquisitions, and strategic investments for NewH2. He has extensive experience in investing in global start-ups and high growth companies with technologies and businesses that are of strategic importance to H&H Group. Akash has experience in multicultural and global environments. Prior to joining H&H Group, he was a Director of Global Consumer and Retail for HSBC for over a decade.
|Mr Mark Masterson||Non-Executive DirectorNon-Executive Chairman||Nov 2019||
Mr Masterson has two decades of experience in the pharmaceutical and healthcare sectors. He began his career with Johnson & Johnson before joining global healthcare giant, Abbott Laboratories (NYSE: ABT) where he held multiple senior positions. Mark also held the role of CEO with Australia's largest private diagnostic imaging network, I-MED. Following the acquisition of I-MED, he was appointed Chairman of Medicines Australia.
|Mr Johannes (Hanno) Jacobus Cappon||Non-Executive Director||Jul 2021||
Mr Cappon has experience in biochemistry, nutrition, health and innovation. He has a background in chemistry, life sciences, nutrition and health innovation and developing new consumer and healthcare solutions for commercialization. Mr Cappon is currently Chief Technology Officer at H&H, a position which he has held since January 2021. Mr Cappon's previous senior roles with international companies include VP R&D Nutritionals & Digestive Health at Bayer Consumer Health, Switzerland, as well as VP R&D Nutricia Medical Nutrition at multinational food company Danone Nutricia, Netherlands, amongst others.
|Mr Stephen Kelly||Company Secretary||Sep 2018||
|Craig Weller||Chief Operating Officer||
|Stephen Kelly||Company Secretary||
|New H2 Limited||14,864,865||14.03%|
|HSBC Custody Nominees (Australia) Limited||10,056,315||9.49%|
|Health And Beauty Enterprise Pty Limited||5,750,000||5.43%|
|Noir Ted Pty Ltd||4,852,329||4.58%|
|Awj Family Pty Ltd||4,445,346||4.20%|
|Sanlam Private Wealth Pty Ltd||2,500,000||2.36%|
|Gp Securities Pty Ltd||2,275,416||2.15%|
|Citicorp Nominees Pty Limited||2,150,592||2.03%|
|Calama Holdings Pty Ltd||1,332,590||1.26%|
|Awj Family Pty Ltd (i)||1,216,084||1.15%|
|Yoix Pty Ltd||1,010,000||0.95%|
|Baker Cook Advisory Pty Ltd||1,000,000||0.94%|
|Jimbzal Pty Ltd||1,000,000||0.94%|
|Twenty Ten Enterprises Pty Ltd||900,050||0.85%|
|Ms Suzanne Taylor||897,671||0.85%|
|National Nominees Limited||887,408||0.84%|
|Jgc Patterson Pty Ltd||800,000||0.76%|
|Symington Pty Ltd||521,360||0.49%|
|Mr Kenneth George Parnell & Mrs Lynette Ann Parnell||500,000||0.47%|
|Bond Street Custodians||441,176||0.42%|
|Mr John Anthony Redpath||425,901||0.40%|